ATE422162T1 - Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen - Google Patents

Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen

Info

Publication number
ATE422162T1
ATE422162T1 AT06838008T AT06838008T ATE422162T1 AT E422162 T1 ATE422162 T1 AT E422162T1 AT 06838008 T AT06838008 T AT 06838008T AT 06838008 T AT06838008 T AT 06838008T AT E422162 T1 ATE422162 T1 AT E422162T1
Authority
AT
Austria
Prior art keywords
predicting
prohibitin
preventing resistance
taxoid compounds
taxoid
Prior art date
Application number
AT06838008T
Other languages
English (en)
Inventor
Bruce Zetter
Sabarni Chatterjee
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE422162T1 publication Critical patent/ATE422162T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y205/00Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018Glutathione transferase (2.5.1.18)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT06838008T 2005-11-17 2006-11-17 Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen ATE422162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73765305P 2005-11-17 2005-11-17

Publications (1)

Publication Number Publication Date
ATE422162T1 true ATE422162T1 (de) 2009-02-15

Family

ID=38067807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06838008T ATE422162T1 (de) 2005-11-17 2006-11-17 Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen

Country Status (7)

Country Link
US (3) US8148086B2 (de)
EP (1) EP1948213B1 (de)
AT (1) ATE422162T1 (de)
AU (1) AU2006318722A1 (de)
CA (1) CA2630214A1 (de)
DE (1) DE602006005084D1 (de)
WO (1) WO2007061922A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061922A2 (en) 2005-11-17 2007-05-31 Children's Medical Center Corporation Methods to predict and prevent resistance to taxoid compounds
US20090258020A1 (en) * 2008-01-07 2009-10-15 Patrys Limited Antibody designated barb3, barb3 related antibodies, and methods of making and using same
WO2013043870A1 (en) * 2011-09-23 2013-03-28 The Board Of Regents Of The University Of Texas System Compositions and methods related to tissue targeting
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
TWI715594B (zh) * 2015-06-24 2021-01-11 日商日東電工股份有限公司 用於麩胱甘肽S轉移酶Pi(GST-π)基因調控之RNA干擾劑
CN108883171A (zh) * 2015-11-13 2018-11-23 麻省理工学院 用于检测和调节癌细胞的方法和组合物
KR101854291B1 (ko) 2016-02-16 2018-05-03 전남대학교산학협력단 프로히비틴 단백질에 대한 항체를 포함하는 혈액암 진단용 조성물 및 이를 포함하는 혈액암 진단용 키트
JP6899201B2 (ja) * 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物
WO2018005991A1 (en) * 2016-07-01 2018-01-04 Luxtera, Inc. Method and system for redundant light sources by utilizing two inputs of an integrated modulator
US20200399681A1 (en) 2018-02-23 2020-12-24 Cornell University Assay for detection of androgen receptor variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1791957B1 (de) * 2004-09-23 2013-07-31 AEterna Zentaris GmbH Prohibitin als ziel für krebstherapie
WO2007057746A2 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
US20070122830A1 (en) * 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Prohibitin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
WO2007061922A2 (en) 2005-11-17 2007-05-31 Children's Medical Center Corporation Methods to predict and prevent resistance to taxoid compounds

Also Published As

Publication number Publication date
US20090312405A1 (en) 2009-12-17
US20160011211A1 (en) 2016-01-14
DE602006005084D1 (de) 2009-03-19
US20130028885A1 (en) 2013-01-31
CA2630214A1 (en) 2007-05-31
WO2007061922A3 (en) 2007-10-18
WO2007061922A2 (en) 2007-05-31
US9151758B2 (en) 2015-10-06
AU2006318722A1 (en) 2007-05-31
EP1948213A2 (de) 2008-07-30
EP1948213B1 (de) 2009-02-04
US8148086B2 (en) 2012-04-03

Similar Documents

Publication Publication Date Title
ATE422162T1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
CY1125027T1 (el) Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CY1118169T1 (el) Λεμφοκυτταρικο αντιγονο 75 (ly75)
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
RU2448096C3 (ru) Диарилгидантоины
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200970738A1 (ru) Ингибиторы активности akt
DK1951759T3 (da) Anti-EGFR-antistoffer
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
ATE483705T1 (de) (lh-ind0l-7-yl)-(pyrimidin-2 -yl-amino) methanon derivate und verwandte verbindungen als igf-rl inhibitoren zur behandlung von krebs
EA200900571A1 (ru) Композиции chk1 ингибиторов
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
EA201170344A1 (ru) Азаиндольные ингибиторы iap

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties